openPR Logo
Press release

Global Active Pharmaceutical Ingredients (API) Market is Anticipated to Grow US$ 186 Bn Globally by 2020 End

04-12-2017 03:24 PM CET | Industry, Real Estate & Construction

Press release from: Persistence Market Research Pvt. Ltd

Global Active Pharmaceutical Ingredients (API) Market

According to a new market report published by Persistence Market Research “Active Pharmaceutical Ingredient (API) Market” the global active pharmaceutical ingredient market was valued at US$ 127 Bn in 2014 and is estimated to reach US$ 186 Bn by 2020 at a CAGR of 6.6% from 2015 to 2020.

Active pharmaceutical ingredient (API) refers to a therapeutically active ingredient or substance combination used in manufacturing a drug product. Production of active pharmaceutical ingredients is a highly sophisticated and technically demanding process. The global active pharmaceutical ingredient market is surging due to the increased demand for pharmaceutical drugs, which in turn is driven by aging population, increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular, neurological and infectious diseases among others. Further, fragmented nature of the pharmaceutical supplies market, brings a smaller profit share to each player.

A Sample of this Report is Available Upon Request @

The global active pharmaceutical ingredient market encompasses geographies such as North America, Asia Pacific, Europe and Rest of the World. North America accounted for the largest segment in the global active pharmaceutical ingredients market in 2014 due to fact that North America is the leading consumer of APIs and API exporters consider North America as the most lucrative market. India and China are the major suppliers of APIs to North America due to low production and labor costs. Moreover, biologics have become one of the top-selling drugs in North America. Thus, the expected market entry of biosimilars with flexible regulatory process would boost the API market in North America. The API market in the U.S. displays high level of competition, with mergers and collaborations between various key players such as Teva Pharmaceutical Industries Ltd., Sandoz (Novartis AG), Mylan, Inc., and Allergen plc.

Additionally, demand for biological APIs is high in the region, as technological developments in the pharmaceutical industry are paving the way for newer biotechnology drugs. These expansion strategies intensify the competition between the global players, which is a result of expected high growth in the API market.

Asia Pacific ranks second due to the factors such as availability of low cost production facilities and cheap labor in countries such as India and China. The cost difference ranges from 30% to 60% if the drugs are manufactured in China or India compared to other countries. Hence, China and India are expected to witness significant growth in the near future due to increase in production capacities and presence of large number of global and domestic players… Thus, Asia-Pacific is the most competitive market in API and the competition is expected to intensify between India and China, as these are the most attractive destinations for pharmaceutical manufacturing.

In Europe pharmacists are offered incentives for substituting branded drugs with generic versions, which contributes to the growth of the API market in the region. Regulations also play a vital role in the API market, as the law disallows development of generic APIs in Europe until patent expiry. However, the governments of various countries in Europe have started supporting the manufacture of generic drugs post the financial crisis. Patent expirations of major blockbuster drugs in Europe during the forecast period would fuel the growth of the API market in the near future.

Request to View Tables of Content @

Demand for generic drugs is increasing not only in developed countries, but also in developing and underdeveloped countries in South America and Africa. Brazil’s health authority Agência Nacional de Vigilância Sanitária (ANVISA) allows the procurement or manufacturing of APIs only for companies registered with ANVISA. Moreover, foreign companies find it difficult to enter the generics market in Brazil, as nearly 80% of the market is controlled by the four local companies namely, EMS, Medley, Eurofarma and Ache/Biosintetica. According to reports published by Mexico’s National Association of Drug Manufacturers (ANAFAM), in 2013 86% of drugs used in Mexico were produced domestically to help curtail rising healthcare costs. Other factors boosting the API market growth in developing regions are cost-efficient manufacturing, large patient pool, rising demand for generic drugs, and improvement in the healthcare infrastructure. For the same reasons, the API market in South America is developing steadily and is likely to witness significant growth during the forecast period.

To Buy Full Report for a Single User @

About Us
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated re-search, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Con-sumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s en-gagement models are highly flexible without compromising on its deep-seated research values.

Persistence Market Research Pvt. Ltd
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Active Pharmaceutical Ingredients (API) Market is Anticipated to Grow US$ 186 Bn Globally by 2020 End here

News-ID: 500227 • Views: 263

More Releases from Persistence Market Research Pvt. Ltd

Global HPMC Capsules Market is expected to reach a Valuation of US$ 554.5 Mn Ove …
HPMC capsules are strictly non-toxic and qualify to be Kosher and Halal-certified, which is why their popularity has grown in several parts of the world. Moreover, these capsules can significantly boost the body metabolism by improving absorption and digestion of protein, fat and carbohydrates. HPMC capsules find their application in the preparation of non-animal based medicines and cosmetics & nutraceuticals products. Persistence Market Research (PMR) recently conducted a study
Vacuum Tissue Processor Technology Most Favored in the Global Tissue Processing …
Persistence Market Research has come up with a fact based analytical research study describing various aspects of the tissue processing systems market across the globe. The analysis on tissue processing systems has been systematically drafted in a new research publication titled “Tissue Processing Systems Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)”. This comprehensive research report focuses on various developments, trends, restraints, opportunities, drivers and challenges impacting revenue growth of
Endodontics Market Is Projected To Grow At A Moderate CAGR During The Period Of …
Endodontics is associated with the dentistry segment. It involves several therapies to protect the human teeth from infections and injuries caused to the dental pulp. Generally, it is concerned with morphology, pathology as well as physiology of dental pulp and the periradicular tissues. Endodontics is important during carrying out root canal procedure in order to reduce the inflammation and to end infection. Modernization has touched the field of endodontics as
Global Home Infusion Therapy Devices Market Driven by Growing Incidence of Pain, …
According to the latest market report published by Persistence Market Research titled ‘Home Infusion Therapy Devices Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025),’ the global Home Infusion Therapy Devices market is expected to expand at a CAGR of 6.8% during the forecast period 2017–2025. Persistence Market Research delivers key insights and presents a revised forecast of the global Home Infusion Therapy Devices market for an eight year period from

All 5 Releases

More Releases for API

Terminating Twitter API Integrations
Thexyz Inc, the leading private email service that protects people and their data announces that a Twitter authentication apps developed by Thexyz will be discontinued and no longer supported. Thexyz focuses on security, privacy, freedom, and an open internet that respects the rights of individuals. It is a goal to work with organizations that share these values and discontinue support for services that do not. Thexyz has developed applications
Tagraxofusp - API Insight, 2018
Tagraxofusp, sold under the brand name of Elzonris, is an Interleukin 3 (IL-3) conjugated truncated diphtheria toxin. It is composed of catalytic and translocation domains of diphtheria toxin fused via Met-His linker to a full-length human IL-3. Download the sample report @ Tagraxofusp was developed by Stemline Therapeutics Inc. and was approved in December 2018, as the first therapy for blastic plasmacytoid dendritic cell neoplasm. This drug achieved approval after
Cabozantinib- API Insight, 2018
Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Download the sample report @ Discovered and developed by Exelixis Inc., its side-effects include increased liver enzymes, diarrhea, low calcium, mouth sores, decreased
Tyk API Management v2.3
After months working-out in the gym, the new version of Tyk is ready to flex its muscles.   Tyk v2.3 is twice as fast, leaner, more extendable and is still available for FREE! London, United Kingdom 8th December, 2016. Tyk Technologies is pleased to announce the v2.3 release of Tyk, the popular open-source API Management platform.   Tyk v2.3 builds upon the success of previous releases. The feedback and contributions from Tyk’s thriving open source community, as well as enterprise clients, drove
Telecom API Helps Application Developers to Integrate Various API Services
Telecom API market represents an overall Application Programming Interface (API) services provided by telecom carriers, service providers and aggregators to application developers in order to create mobile applications. Telecom API helps application developers to integrate various services such as payment, voice, SMS and WebRTC into their mobile application. This helps application developers to enhance their customer experience and market their mobile applications among end-users. Telecom API provides many benefits to
Biotech API Surging Worldwide
According to a new research report by RNCOS, entitled “Global Biotech API Market Analysis”, geographies across the world are showing insurgent growth in the biotech API Industry. The US occupied more than half of the share in the global market in 2011, and is the largest producer of biotech APIs. Western European countries occupy around 15% share globally among which, the UK is the largest producer of biotechnology-based APIs. The